Epidermolysis Bullosa (EB) is a category of rare genetic disorders involving the skin and skin-like tissues. EB is generally inherited from one or both parents who have been diagnosed with EB or carry as mutated EB gene. Rarely, EB can also occur in an individual due to a new genetic mutation, which might have been absent in either or both parents. People suffering from EB have fragile skin which causes blisters that can lead to wounds which are difficult to heal. Low prevalence, lack of data, and no available medications make EB a non-curable disease. A Severe form of EB can be a cause of cancer. At present EB is categorized into EB simplex, Junctional EB, Dystrophic EB, and Kindler Syndrome.
The global Epidermolysis Bullosa market is projected to grow from US$1,313.346 million in 2017 to US$1,644.712 million in 2022, at a compound annual growth rate (CAGR) of 4.60% over the forecast period.
This section provides an anatomy of the research process followed for calculating market size and forecasts along with a list of the secondary data sources used and the primary inputs which were taken for data validation. It also provides an outline of the various segmentations which have been covered as part of the report.
In this section, the entire Epidermolysis Bullosa Care and Treatment market is explained along with the causes, diagnosis, and prevention of the disease, the various drivers, restraints, and opportunities to the market and the prevalence of the disease based on age, gender and region. A product pipeline of various drugs and vaccines for therapeutic action have been mentioned along with innovations in the market. Certain regulations specific to the industry are also listed out, followed by a detailed scenario analysis.
Epidermolysis Bullosa Care and Treatment market has been segmented based on the type and geography as below:
Epidermolysis Bullosa Care
Europe Middle East and Africa
Middle East and Africa
This section deals with major players in the market, their market shares, products, growth strategies, financials, and recent investments among others. Key industry players profiled in the report are RegeneRx Biopharma, InMed Pharmaceuticals Inc, Amicus Therapeutics, and TWi Pharmaceuticals, Inc. among others.